Primary care of the kidney transplant recipient
1. Fluvastatin, pravastatin, and atorvastatin seem to have a more favorable safety profile in kidney transplant recipients.
2. Because there is no evidence that a particular class of antihypertensive agents is more effective than other classes, the choice of medications should be individualized and based on various comorbidities.
3. Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines suggest goal blood pressure less than 130/80 mm Hg for all kidney transplant recipients.
4. NODAT should be carefully monitored for and develops in up to 54% of kidney transplant patients, particularly in the first 6 months.
5. Studies have demonstrated a rapid decrease in bone mineral density in the first 6 to 12 months after transplantation.